Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Moxifloxacin
Drug ID BADD_D01501
Description Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Indications and Usage For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).
Marketing Status approved; investigational
ATC Code J01MA14; S01AE07
DrugBank ID DB00218
KEGG ID D08237
MeSH ID D000077266
PubChem ID 152946
TTD Drug ID D0ZV0Z
NDC Product Code 65977-0038; 51407-321; 63629-8357; 0378-5430; 65862-840; 72189-321; 16714-643; 50090-6357; 55111-112; 70518-3713; 80425-0239; 50090-5833; 53002-2723; 68180-421; 61919-553; 72789-233; 60505-0582; 68180-422; 72189-334; 17478-519; 31722-845; 0904-6406; 12527-0517; 50090-3147
UNII U188XYD42P
Synonyms Moxifloxacin | 1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid | Octegra | Proflox | Moxifloxacin Hydrochloride | Avelox | Avalox | Izilox | Actira | BAY 12-8039 | BAY 12 8039 | BAY-12-8039 | BAY 128039 | BAY-128039 | BAY128039
Chemical Information
Molecular Formula C21H24FN3O4
CAS Registry Number 151096-09-2
SMILES COC1=C2C(=CC(=C1N3CC4CCCNC4C3)F)C(=O)C(=CN2C5CC5)C(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Basophil count increased13.01.06.002---
Blepharospasm06.05.01.001; 17.17.02.0010.000269%-
Blindness06.02.10.003; 17.17.01.0030.000202%-
Blister12.01.06.002; 23.03.01.001---
Blood albumin13.09.01.012---
Blood bilirubin increased13.03.04.018--
Blood chloride increased13.11.01.005---
Blood creatinine increased13.13.01.004--
Blood glucose decreased13.02.02.001---
Blood glucose increased13.02.02.002---
Blood lactate dehydrogenase increased13.04.02.002--
Blood pressure increased13.14.03.005---
Blood triglycerides increased13.12.03.001---
Blood urea increased13.13.01.006---
Blood uric acid increased13.02.04.001---
Bradycardia02.03.02.002---
Bronchospasm10.01.03.012; 22.03.01.004--
Burning sensation08.01.09.029; 17.02.06.0010.000458%-
Cardiac arrest02.03.04.001--
Cardiac failure02.05.01.001--
Cardiac failure congestive02.05.01.002---
Cerebrovascular accident17.08.01.007; 24.03.05.0010.000135%
Chest discomfort02.02.02.009; 08.01.08.019; 22.12.02.002---
Chest pain02.02.02.011; 08.01.08.002; 22.12.02.003---
Chills08.01.09.001; 15.05.03.016--
Choking sensation19.01.02.002; 22.12.03.004---
Chromaturia20.02.01.002--
Cold sweat08.01.03.024; 23.02.03.002---
Confusional state17.02.03.005; 19.13.01.0010.000135%
Conjunctival oedema06.04.01.0010.000606%-
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 11 Pages